In the group treated with finasteride, they demonstrated an association between NPAS2 and prostate cancer risk that was lacking in the placebo group.43 This suggests that NPAS2 variation may increase risk of prostate cancer through androgen receptor–dependent signaling. Here, NPAS2 is linked to prostate cancer.